Last reviewed: July 6, 2026 Last updated: July 6, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
As a result, LegitScript expects to see problematic behavior including illicit compounding, especially from overseas manufacturers, and counterfeit versions of brand name drugs for sale
These findings suggest a substantial degree of central sensitization in cirrhosis, highlighting nociplastic pain as a crucial component of chronic pain in these patients (68, 81)
Phase 3 (TRIUMPH-4): Topline results announced December 2025
Dehydration and insulinopenia are necessary and sufficient for euglycemic ketoacidosis in SGLT2 inhibitor-treated rats
According to the PIONEER 2 clinical trial, Rybelsus 14mg demonstrated superior A1C reduction compared to Jardiance 25mg (1.3% vs 0.9%) at 26 weeks